|

Dacomitinib Clinical Trials

2 actively recruiting trials

Also known as: Vizimpro

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • The Netherlands Cancer Institute1
  • Shanghai Chest Hospital1

Indications

  • Cancer2
  • Neoplasia1
  • Tumors1
  • Neoplasm1
  • Non-small Cell Lung Cancer (NSCLC)1

Other2 trials

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
Phase 1/2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.